Login to Your Account



Fedora Turning Heads with Beta-Lactamase Inhibitors

By Marie Powers
Staff Writer

Friday, September 7, 2012
Newly launched Canadian biotech Fedora Pharmaceuticals Inc. has landed in the antibiotics space with multiple beta-lactamase inhibitor candidates in the lead optimization stage of preclinical development and investigational new drug-enabling studies expected to begin next year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription